{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T02:11:46Z","timestamp":1714961506317},"reference-count":90,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["cancertreatmentreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.ctrv.2012.12.013","type":"journal-article","created":{"date-parts":[[2013,2,14]],"date-time":"2013-02-14T03:31:48Z","timestamp":1360812708000},"page":"602-609","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Open questions in the management of mantle cell lymphoma"],"prefix":"10.1016","volume":"39","author":[{"given":"Zhi-Ming","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuele","family":"Zucca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Ghielmini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2012.12.013_b0005","series-title":"WHO Classification of Tumours of Haematopoetic and Lymphoid Tissues","first-page":"229","article-title":"Mantle cell lymphoma","author":"Swerdlow","year":"2008"},{"key":"10.1016\/j.ctrv.2012.12.013_b0010","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3816\/CLM.2009.n.055","article-title":"Mantle cell lymphoma: biological insights and treatment advances","volume":"9","author":"Leonard","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.ctrv.2012.12.013_b0015","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.3109\/10428194.2012.656628","article-title":"Survival trends in mantle cell lymphoma in the United States over 16 years 1992\u20132007","volume":"53","author":"Chandran","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ctrv.2012.12.013_b0020","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2009-02-179739","article-title":"How I treat mantle cell lymphoma","volume":"114","author":"Ghielmini","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2012.12.013_b0025","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1182\/blood-2011-12-400580","article-title":"Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma","volume":"119","author":"Nygren","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2012.12.013_b0030","doi-asserted-by":"crossref","first-page":"4315","DOI":"10.1182\/blood-2005-04-1753","article-title":"Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling","volume":"106","author":"Fu","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2012.12.013_b0035","doi-asserted-by":"crossref","first-page":"5683","DOI":"10.1182\/blood-2007-10-118794","article-title":"Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas","volume":"111","author":"Wlodarska","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2012.12.013_b0040","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.critrevonc.2011.05.001","article-title":"Mantle cell lymphoma","volume":"82","author":"Cortelazzo","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ctrv.2012.12.013_b0045","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ajh.23176","article-title":"Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management","volume":"87","author":"Vose","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ctrv.2012.12.013_b0050","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1053\/j.seminhematol.2011.03.008","article-title":"Treatment of elderly patients with mantle cell lymphoma","volume":"48","author":"Kluin-Nelemans","year":"2011","journal-title":"Semin Hematol"},{"key":"10.1016\/j.ctrv.2012.12.013_b0055","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1053\/j.seminhematol.2011.06.002","article-title":"Treatment of younger patients with mantle cell lymphoma","volume":"48","author":"Harel","year":"2011","journal-title":"Semin Hematol"},{"key":"10.1016\/j.ctrv.2012.12.013_b0060","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.12.013_b0065","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/(SICI)1097-0142(19980201)82:3<567::AID-CNCR20>3.0.CO;2-Z","article-title":"Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors","volume":"82","author":"Bosch","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2012.12.013_b0070","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1097\/01.MP.0000030088.28684.5B","article-title":"Cerebrospinal fluid involvement in mantle cell lymphoma","volume":"15","author":"Valdez","year":"2002","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ctrv.2012.12.013_b0075","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1097\/01.pas.0000208899.15859.cb","article-title":"Gastrointestinal involvement in mantle cell lymphoma: a prospective clinic, endoscopic, and pathologic study","volume":"30","author":"Salar","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ctrv.2012.12.013_b0080","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2012.12.013_b0085","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1535-6108(03)00028-X","article-title":"The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma","volume":"3","author":"Rosenwald","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctrv.2012.12.013_b0090","doi-asserted-by":"crossref","first-page":"4966","DOI":"10.1200\/JCO.2007.12.0410","article-title":"Five-gene model to predict survival in mantle-cell lymphoma using frozen or formalin-fixed, paraffin-embedded tissue","volume":"26","author":"Hartmann","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.12.013_b0095","doi-asserted-by":"crossref","first-page":"4939","DOI":"10.1182\/blood-2011-07-370122","article-title":"Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis","volume":"119","author":"Iqbal","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2012.12.013_b0460","doi-asserted-by":"crossref","unstructured":"Hsiao SC, Cortada IR, Colomo L, et al. SOX11 is useful in differentiating cyclin D1-positive diffuse large B-cell lymphoma from mantle cell lymphoma. Histopathology 2012;May 29. [Epub ahead of print].","DOI":"10.1111\/j.1365-2559.2012.04260.x"},{"key":"10.1016\/j.ctrv.2012.12.013_b0105","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1365-2141.2008.07329.x","article-title":"The subcellular Sox11 distribution pattern identifies subsets of mantle cell lymphoma: correlation to overall survival","volume":"143","author":"Wang","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2012.12.013_b0110","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1158\/0008-5472.CAN-09-3419","article-title":"Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma","volume":"70","author":"Fern\u00e0ndez","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2012.12.013_b0115","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2008.19.6121","article-title":"Outcome of deferred initial therapy in mantle-cell lymphoma","volume":"27","author":"Martin","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.12.013_b0120","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1200\/JCO.1995.13.11.2819","article-title":"Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin\u2019s lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group","volume":"13","author":"Teodorovic","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.12.013_b0125","first-page":"836","article-title":"Prednimustine, mitoxantrone (PmM) vs. cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin\u2019s lymphoma. German Low-Grade Lymphoma Study Group","volume":"10","author":"Unterhalt","year":"1996","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2012.12.013_b0130","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.20.5.1288","article-title":"Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival","volume":"20","author":"Howard","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.12.013_b0135","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1365-2141.2011.08820.x","article-title":"VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study","volume":"155","author":"Chang","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2012.12.013_b0140","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1200\/JCO.2010.31.1142","article-title":"Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma","volume":"29","author":"Ruan","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.12.013_b0465","doi-asserted-by":"crossref","unstructured":"Smith MR, Li H, Gordon L, et al. Phase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Immunochemotherapy Followed by Yttrium-90-Ibritumomab Tiuxetan in Untreated Mantle-Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499. J Clin Oncol 2012;Jul 30. [Epub ahead of print].","DOI":"10.1200\/JCO.2012.42.2444"},{"key":"10.1016\/j.ctrv.2012.12.013_b0150","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/hon.2900070505","article-title":"Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosis","volume":"7","author":"Meusers","year":"1989","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.ctrv.2012.12.013_b0155","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/cncr.22093","volume":"107","author":"Nickenig","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2012.12.013_b0160","article-title":"Immunochemotherapy (R-MCP) in advanced mantle cell lymphoma is not superior to chemotherapy (MCP) alone: 50 months up date of the OSHO phase III study (OSHO#39)","volume":"19","author":"Herold","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2012.12.013_b0165","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.405.405","volume":"114","author":"Rummel","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2012.12.013_b0170","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.439.439","article-title":"R-CHOP versus R-FC followed by maintenance with rituximab versus interferon-alfa: outcome of the first randomized trial for elderly patients with mantle cell lymphoma","volume":"118","author":"Kluin-Nelemans","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2012.12.013_b0175","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma","volume":"367","author":"Kluin-Nelemans","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2012.12.013_b0180","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1200\/JCO.1998.16.12.3803","article-title":"Hyper-CVAD and high-dose methotrexate\/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma","volume":"16","author":"Khouri","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.12.013_b0185","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/10428190009053541","article-title":"Untreated aggressive mantle cell lymphoma: results with intensive chemotherapy without stem cell transplant in elderly patients","volume":"39","author":"Romaguera","year":"2000","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ctrv.2012.12.013_b0190","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","article-title":"High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine","volume":"23","author":"Romaguera","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.12.013_b0195","doi-asserted-by":"crossref","first-page":"121a","DOI":"10.1182\/blood.V110.11.387.387","article-title":"A multicenter trial of hyper-CVAD+rituxan in patients with newly diagnosed mantle cell lymphoma","volume":"110","author":"Epner","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2012.12.013_b0200","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.3050.3050","article-title":"Rituximab plus hypercvad alternating with high dose methotrexate and cytarabine for patients with newly diagnosed mantle cell lymphoma. a multicenter trial from GISL","volume":"112","author":"Merli","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2012.12.013_b0205","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1365-2141.2011.08958.x","article-title":"Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from gruppo italiano studio linfomi","volume":"156","author":"Merli","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2012.12.013_b0210","first-page":"425","article-title":"Rituximab and DHAP followed by intensive therapy with autologous stem-cell transplantation as first-line therapy for mantle cell lymphoma","volume":"91","author":"de Guibert","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2012.12.013_b0215","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/sj.leu.2402406","article-title":"Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study","volume":"16","author":"Lefr\u00e8re","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2012.12.013_b0220","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3324\/haematol.10608","article-title":"Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome","volume":"92","author":"Dreger","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2012.12.013_b0225","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1365-2141.2008.07498.x","article-title":"High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients","volume":"144","author":"Van\u2019t Veer","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2012.12.013_b0230","doi-asserted-by":"crossref","unstructured":"Delarue R, Haioun C, Ribrag V, et al. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation (ASCT) in mantle cell lymphoma (MCL): a phase II study from the GELA. Blood 2012 Jun 20. [Epub ahead of print].","DOI":"10.1182\/blood-2011-09-370320"},{"key":"10.1016\/j.ctrv.2012.12.013_b0235","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2141.2012.09174.x","article-title":"Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC+autologous stem-cell support: still very long survival but late relapses do occur","volume":"158","author":"Geisler","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2012.12.013_b0240","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","volume":"23","author":"Lenz","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.12.013_b0245","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.3049.3049","article-title":"The addition of rituximab to first-line chemotherapy (R-CHOP) results in superior response rates, time to treatment failure and response duration in patients with advanced stage mantle cell lymphoma: long term results of a randomized GLSG trial","volume":"112","author":"Hoster","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2012.12.013_b0250","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.769.769","article-title":"Early consolidation with myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission in mantle cell lymphoma: long term follow up of a randomized trial of the","volume":"112","author":"Dreyling","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2012.12.013_b0255","first-page":"300","article-title":"European Mantle Cell Lymphoma Network: an update on current first line trials [abstract]","volume":"19","author":"Dreyling","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2012.12.013_b0260","volume":"116","author":"Hermine","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2012.12.013_b0265","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2141.2010.08228.x","article-title":"Ten-year follow-up after intense chemoimmunotherapy with rituximab-HyperCVAD alternating with rituximab-high dose methotrexate\/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma","volume":"150","author":"Romaguera","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2012.12.013_b0270","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1200\/JCO.2005.04.164","article-title":"Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK)","volume":"23","author":"Ghielmini","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.12.013_b0275","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/jnci\/djk152","article-title":"Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis","volume":"99","author":"Schulz","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2012.12.013_b0280","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1182\/blood-2011-07-369629","article-title":"Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL database","volume":"119","author":"LaCasce","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2012.12.013_b0285","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2012.12.013_b0290","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood-2005-07-2845","article-title":"Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma","volume":"107","author":"Pott","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2012.12.013_b0295","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"issue":"Suppl 4","key":"10.1016\/j.ctrv.2012.12.013_b0300","article-title":"R-CHOP versus R-FC followed maintenance with rituximab or IFN: first results of a randomized trial for elderly patients with mantle cell lymphoma","volume":"22","author":"Kluin-Nelemans","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2012.12.013_b0305","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00432-005-0023-2","article-title":"Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin\u2019s lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19)","volume":"132","author":"Herold","year":"2006","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.12.013_b0310","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/annonc\/mdm447","article-title":"Central nervous system involvement in mantle cell lymphoma","volume":"19","author":"Ferrer","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2012.12.013_b0315","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1365-2141.2009.07835.x","article-title":"Mantle cell lymphoma with central nervous system involvement: frequency and clinical features","volume":"147","author":"Gill","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2012.12.013_b0320","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s002770050491","article-title":"Central nervous system involvement in patients with mantle cell lymphoma","volume":"78","author":"Oinonen","year":"1999","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ctrv.2012.12.013_b0325","first-page":"2660","article-title":"Central nervous system (CNS) relapse in a population of 143 patients (Pts) with mantle cell lymphoma (MCL) from two centers","volume":"118","author":"Conconi","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"Suppl 1","key":"10.1016\/j.ctrv.2012.12.013_b0330","article-title":"Incidence, characteristics and outcome of CNS involvement in mantle cell lymphoma: a multicentre retrospective analysis from the European Mantle Cell Lymphoma Network","volume":"97","author":"Cheah","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2012.12.013_b0335","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/annonc\/mdh425","article-title":"Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study","volume":"15","author":"Brugger","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2012.12.013_b0340","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1200\/JCO.2008.21.3116","article-title":"Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma","volume":"27","author":"Andersen","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.12.013_b0345","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","volume":"108","author":"Forstpointner","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2012.12.013_b0350","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.1758.1758","article-title":"High response rate after 4 courses of R-DHAP in untreated mantle cell lymphoma (MCL) patients in the ongoing phase III randomized GOELAMS and GELA LyMa Trial","volume":"116","author":"Le Gouill","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2012.12.013_b0355","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1093\/annonc\/mdg414","article-title":"Limited-stage mantle-cell lymphoma","volume":"14","author":"Leitch","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2012.12.013_b0360","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.ijrobp.2006.02.011","article-title":"Highly effective local control and palliation of mantle cell lymphoma with involved-field radiation therapy (IFRT)","volume":"65","author":"Rosenbluth","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctrv.2012.12.013_b0365","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.2681.2681","article-title":"High complete response rates with dose dense\/dose intense chemotherapy plus radioimmunotherapy in high risk diffuse large B cell and mantle cell lymphoma","volume":"118","author":"Beaven","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2012.12.013_b0370","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1080\/10428190701851364","article-title":"Therapeutic options in mantle cell lymphoma","volume":"49","author":"Gill","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ctrv.2012.12.013_b0375","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/sj.bmt.1701400","article-title":"High-dose therapy with stem cell transplantation for mantle cell lymphoma: results and prognostic factors, a single center experience","volume":"22","author":"Milpied","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ctrv.2012.12.013_b0380","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.3563.3563","article-title":"Autologous stem cell transplantation in mantle cell lymphoma: total body irradiation (TBI) plus cyclophosphamide (or melphalan) is not superior to beam, a single institution experience","volume":"116","author":"Peterlin","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2012.12.013_b0385","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1046\/j.1365-2141.2003.04140.x","article-title":"Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries","volume":"120","author":"Vandenberghe","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2012.12.013_b0390","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.688.688","article-title":"Is there still a place for total body irradiation (TBI) in the conditioning regimen of autologous stem cell transplantation in mantle cell lymphoma?: a retrospective study from the Lymphoma Working Party of the EBMT","volume":"116","author":"Rubio","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2012.12.013_b0395","doi-asserted-by":"crossref","unstructured":"Le Gouill S, Kr\u00f6ger N, Dhedin N, et al. Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed\/refractory mantle cell lymphoma: a multicenter experience. Ann Oncol 2012 Mar 22. [Epub ahead of print].","DOI":"10.1093\/annonc\/mds054"},{"key":"10.1016\/j.ctrv.2012.12.013_b0400","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1182\/blood-2008-10-184200","article-title":"Mature results of the M.D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma","volume":"113","author":"Tam","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2012.12.013_b0405","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.bbmt.2004.09.007","article-title":"Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma","volume":"11","author":"Kasamon","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.ctrv.2012.12.013_b0410","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdn656","article-title":"Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study","volume":"20","author":"Goy","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2012.12.013_b0415","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1093\/annonc\/mdr450","article-title":"Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS","volume":"23","author":"Houot","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2012.12.013_b0420","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/S1470-2045(10)70210-2","article-title":"New drugs for aggressive B-cell and T-cell lymphomas","volume":"11","author":"Murawski","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2012.12.013_b0425","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1200\/JCO.2004.03.071","article-title":"Phase II study of denileukin diftitox for relapsed\/refractory B-Cell non-Hodgkin\u2019s lymphoma","volume":"22","author":"Dang","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.12.013_b0430","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2009.27.15_suppl.8569","article-title":"Efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory mantle-cell lymphoma: results from an international study (NHL-003)","volume":"27","author":"Reeder","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.12.013_b0435","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2141.2009.07626.x","article-title":"Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma","volume":"145","author":"Habermann","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2012.12.013_b0440","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/annonc\/mdq626","article-title":"An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin\u2019s lymphoma","volume":"22","author":"Witzig","year":"2011","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2012.12.013_b0445","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(12)70200-0","article-title":"Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1\/2 clinical trial","volume":"13","author":"Wang","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2012.12.013_b0450","doi-asserted-by":"crossref","first-page":"416","DOI":"10.3324\/haematol.2011.051813","article-title":"Salvage treatment with lenalidomide and dexamethasone in relapsed\/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers","volume":"97","author":"Zaja","year":"2012","journal-title":"Haematologica"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573721300008X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573721300008X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T01:37:14Z","timestamp":1714959434000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030573721300008X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":90,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S030573721300008X"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2012.12.013","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Open questions in the management of mantle cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2012.12.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}